Private placement of 25,191,473 shares of Class A common stock at $1.89 per share under the Cambridge Subscription Agreement
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Richard Adcock
CEO and President
|
57 | Not stated | $12,716,953 | |
|
David Sachs
CFO
|
48 |
Since 2021
5 years
|
$4,244,543 | |
|
Regan Lauer
Chief Accounting Officer
|
56 |
Since 2021
5 years
|
$745,313 | |
|
Patrick Soon-Shiong
Also a director
Founder, Global Chief Scientific and Medical Officer
|
73 | Not stated | $12,293,255 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Private placement of 25,191,473 shares of Class A common stock at $1.89 per share under the Cambridge Subscription Agreement
Cambridge Nominating Agreement giving Cambridge the right to designate one Board nominee, held by Dr. Soon-Shiong
Convertible promissory note combining Tranche 1 and Tranche 2 December 2023 notes, Term SOFR plus 8.0%, maturing December 31, 2027
Convertible promissory note at Term SOFR plus 8.0%, due September 11, 2026, later converted into common stock
Promissory note at Term SOFR plus 8.0%, later extended and converted into common stock
Promissory note with up to three $10.0 million advances at Term SOFR plus 8.0%
Amended and restated shared services agreement under which NantWorks provides support services at cost plus allocations
Facility license agreement with NantWorks for the Culver City office, laboratory and cGMP manufacturing facility
Operating leases of certain assets with entities controlled by NantWorks
Multiple agreements with the Clinic to conduct clinical trials and provide transition services for product candidates
Loading...